Results 1 to 10 of about 995,444 (269)

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.

The Journal of the National Comprehensive Cancer Network, 2023
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive
A. Benson, M. D'Angelica, T. Abrams, D. Abbott, Aijaz Ahmed, D. Anaya, R. Anders, C. Are, Melinda Bachini, David Binder, M. Borad, C. Bowlus, Daniel B. Brown, Adam M. Burgoyne, Jason A. Castellanos, P. Chahal, J. Cloyd, A. Covey, E. Glazer, W. Hawkins, R. Iyer, R. Jacob, Lawrence Jennings, R. Kelley, R. Kim, Matthew Levine, M. Palta, James Park, Steven Raman, S. Reddy, Sean Ronnekleiv-Kelly, V. Sahai, Gagandeep Singh, S. Stein, A. Turk, J. Vauthey, A. Venook, A. Yopp, Nicole R Mcmillian, Ryan Schonfeld, Cindy Hochstetler   +40 more
semanticscholar   +1 more source

Publication Trends of Research on Gallbladder Cancer During 2001–2021: A 20-Year Bibliometric Analysis

Frontiers in Oncology, 2022
Gallbladder cancer (GBC) is one of the lethal cancers with an extremely poor prognosis. In the recent 20 years, research on GBC has developed rapidly.
Wentao Sun, Wentao Sun, Wentao Sun, Wenze Wan, Wenze Wan, Wenze Wan, Zhihui Gao, Zhihui Gao, Zhihui Gao, Tao Suo, Tao Suo, Tao Suo, Sheng Shen, Sheng Shen, Sheng Shen, Houbao Liu, Houbao Liu, Houbao Liu   +17 more
doaj   +1 more source

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Liver international (Print), 2023
The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.
M. Rimini, L. Fornaro, S. Lonardi, M. Niger, D. Lavacchi, T. Pressiani, J. Lucchetti, G. Giordano, A. Pretta, E. Tamburini, C. Pirrone, I. Rapposelli, A. Diana, E. Martinelli, I. Garajová, Francesca Simionato, M. Schirripa, V. Formica, C. Vivaldi, E. Caliman, M. Rizzato, Valentina Zanuso, F. Nichetti, L. Angotti, M. Landriscina, M. Scartozzi, M. Ramundo, A. Pastorino, B. Daniele, Noemi Cornara, M. Persano, Eleonora Gusmaroli, Riccardo Cerantola, F. Salani, F. Ratti, L. Aldrighetti, S. Cascinu, L. Rimassa, L. Antonuzzo, A. Casadei‐Gardini   +39 more
semanticscholar   +1 more source

Development and validation of a nomogram to predict overall survival in patients with incidental gallbladder cancer: A retrospective cohort study

Frontiers in Oncology, 2023
ObjectiveThe aim of this study was to develop and validate a nomogram to predict the overall survival of incidental gallbladder cancer.MethodsA total of 383 eligible patients with incidental gallbladder cancer diagnosed in Shanghai Eastern Hepatobiliary ...
Zhi-Hua Xie, Xuebing Shi, Ming-Qi Liu, Jinghan Wang, Yong Yu, Ji-Xiang Zhang, Kai-Jian Chu, Wei Li, Rui-Liang Ge, Qing-Bao Cheng, Xiao-Qing Jiang   +10 more
doaj   +1 more source

Bile Duct Segmentation Methods Under 3D Slicer Applied to ERCP: Advantages and Disadvantages [PDF]

International Journal of Biomedical Engineering and Clinical Science, 2023, 9 (4), pp.66-74, 2023
This article presents an evaluation of biliary tract segmentation methods used for 3D reconstruction, which may be very usefull in various critical interventions, such as endoscopic retrograde cholangiopancreatography (ERCP), using the 3D Slicer software.
arxiv   +1 more source

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

Journal of hepato-biliary-pancreatic sciences, 2022
Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past ...
T. Ioka, M. Kanai, Shogo Kobayashi, D. Sakai, H. Eguchi, Hideo Baba, S. Seo, A. Taketomi, T. Takayama, H. Yamaue, Masahiro Takahashi, M. Sho, K. Kamei, J. Fujimoto, M. Toyoda, J. Shimizu, T. Goto, Y. Shindo, K. Yoshimura, E. Hatano, Hiroaki Nagano   +20 more
semanticscholar   +1 more source

Controversies and Considerations on Surgical Treatment of Gallbladder Cancer

Zhongliu Fangzhi Yanjiu, 2021
Gallbladder cancer is a high malignancy which is predisposed to invade adjacent organs and have lymph node metastasis. Gallbladder cancer is not sensitive to radiotherapy or chemotherapy with the worst prognosis among biliary tract cancers.
LI Wei, WANG Jinghan, MA Wencong, SHI Xuebing, WU Xiaobing, JIANG Xiaoqing   +5 more
doaj   +1 more source

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

Cancers, 2021
Simple Summary Over the last decade, immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have dramatically changed the therapeutic algorithm of several ...
A. Rizzo, A. Ricci, G. Brandi
semanticscholar   +1 more source

Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis

World Journal of Surgical Oncology, 2023
Background The optimal timing of surgery after neoadjuvant chemotherapy (NAC) in patients with synchronous colorectal cancer liver metastases (SLM) remains controversial.
Yaoqun Wang, Ningyuan Wen, Xianze Xiong, Jiong Lu, Bei Li, Nansheng Cheng   +5 more
doaj   +1 more source

Identification of crucial lncRNAs and mRNAs in liver regeneration after portal vein ligation through weighted gene correlation network analysis

BMC Genomics, 2022
Background Portal vein ligation (PVL)-induced liver hypertrophy increases future liver remnant (FLR) volume and improves resectability of large hepatic carcinoma.
Yan Zhu, Zhishuai Li, Jixiang Zhang, Mingqi Liu, Xiaoqing Jiang, Bin Li   +5 more
doaj   +1 more source